SELLAS Life Sciences

SELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies for a wide range of cancer indications. The company’s lead product candidate is galinpepimut-S (GPS), a targeted peptide-based cancer immunotherapy that has entered Phase III clinical trials for the treatment of acute myeloid leukemia and is in multi-phase research stages as a potential treatment for ovarian cancer.